| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10486382 | Value in Health | 2011 | 10 Pages |
Abstract
Bevacizumab does not appear to be cost-effective when added to chemotherapy in patients with advanced NSCLC, based on approximate cost-effectiveness thresholds that have been identified in the United States. These results may inform decision-makers about resource allocation for NSCLC care.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Bernardo MD, MS, Scott MD, PhD,